GenEdit is a next-generation genome editing company

We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients.

 
 

New era of genome editing

CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications.

In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, developing therapeutics based on the CRISPR system has been challenging because of delivery problems.


DSC_8244.jpg

What we do?

The development of safe and efficient delivery vehicles for CRISPR/Cas9 therapeutics is still an unmet medical need and is necessary for the translation of CRISPR/Cas9 technologies into the clinic.

GenEdit has developed a new delivery vehicle for Cas9/CRISPR based therapeutics, which can encapsulate Cas9 protein, guide RNA, and donor DNA, into a single nanoparticle for more efficient homology directed repair. 

We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.